供者淋巴细胞输注治疗小鼠H22肝癌的实验研究-东南大学学报医学版

供者淋巴细胞输注治疗小鼠H22肝癌的实验研究

单位：东南大学附属中大医院,肿瘤科,江苏,南京,210009

分类号：R730.5, R735.7, R-33

出版年·卷·期（页码）：2005·24·第三期（194-197）

摘要：

目的:观察供者淋巴细胞输注(DLI)对小鼠H22肝癌的治疗作用.方法:荷瘤昆明小鼠分荷瘤对照组(A组)、5-氟脲嘧啶(5-FU)化疗组(B组)、DLI组(C组)及5-FU加DLI组(D组)4组.比较各组小鼠生存期、抑瘤率及瘤体病理检查结果,检测NK细胞及IL-2的活性.结果: B、C组生存时间长于A组(P<0.01),D组长于C组(P<0.01);B、C、D各组抑瘤率依次为61.3%、34.7%、89.5%;C、D 两组NK细胞及IL-2活性明显高于A、B组(P<0.05) ;病理观察见C、D组大量炎性细胞浸润.结论:DLI对小鼠H22肝癌有治疗作用,是一种潜在可行的实体瘤细胞过继免疫治疗方法.

Objective To explore the effect of donor lymphocyte infusion on H22 hepatoma mice. Methods Forty H22 hepatoma mice were evenly divided into control group(group A),5FU group(group B),DLI group (group C), and 5FU+DLI group (group D). Survival time, tumor inhibitory rates, histopathologic changes, NK cell activities and interleukin-2 production were investigated. Results The survival time of group B and C was longer than group A (P<0.01) and there was a significant difference between group D and C (P<0.01). The tumor inhibitory rates of group B,C,D were 61.3%,34.7%,89.5%. Compared with group A and B, NK cells activities and interleukin-2 production were higher in group C and D (P<0.05). A lot of inflammatory cells could be seen under optic microscopy in group C and D. Conclusion Allogeneic lymphocytes infusion has antineoplastic effects on H22 hepatic cancer in mice. It is a potential and feasible adoptive cellular immunotherapy for solid tumor.

参考文献：

[1] 吕艳, 谢蜀生, 张庆殷. 供体脾细胞输注诱导小鼠移植耐受及其机理的研究. 中华微生物学和免疫学杂志2001(2)
[2] van de LOOSDRECHT A A, BEELEN R H, OSSENKOPPELE G J. A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. 1994. doi:10.1016/0022-1759(94)90034-5
[3] 孙丰润, 邱世翠, 张循格. 小叶女贞对小鼠淋巴细胞增殖和IL-2产生的影响. 滨州医学院学报2003(1). doi:10.3969/j.issn.1001-9510.2003.01.001
[4] 曹履先. 供者淋巴细胞输注的临床应用. 白血病·淋巴瘤2001(4). doi:10.3760/cma.j.issn.1009-9921.2001.04.003
[5] Hentschke P, BARKHOLT L, UZUNEL M. Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. 2003(4). doi:10.1038/sj.bmt.1703811
[6] BREGNI M, DODERO A, PECCATORI J. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. 2002(11). doi:10.1182/blood.V99.11.4234
[7] UENO N T, CHENG Y C, RONDON G. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. 2003
[8] Dudley M E, WUNDERLICH J R, ROBBINS P F. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. 2002(5594). doi:10.1126/science.1076514
[9] 徐开林, 居建平, 潘秀英. 非清除性异基因骨髓移植治疗小鼠白血病的实验研究. 中华血液学杂志2003(7)
[10] Bishop M R, FOWLER D H, MARCHIGIANI D. Allogenic lymphocytes induce tumor regression of advanced metastatic breast cancer. 2004. doi:10.1200/JCO.2004.01.127
[11] 杜彩文. 植物抗肿瘤反应研究进展. 国外医学(肿瘤学分册)2001(6). doi:10.3760/cma.j.issn.1673-422X.2001.06.011

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录